Evaxion Biotech Past Earnings Performance
Past criteria checks 0/6
Evaxion Biotech's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 116.1% per year.
Key information
-3.5%
Earnings growth rate
13.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 116.1% |
| Return on equity | -15,487.8% |
| Net Margin | -347.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Revenue & Expenses Breakdown
How Evaxion Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -11 | 8 | 11 |
| 30 Jun 24 | 0 | -15 | 9 | 11 |
| 31 Mar 24 | 0 | -15 | 9 | 11 |
| 31 Dec 23 | 0 | -22 | 10 | 12 |
| 30 Sep 23 | 0 | -24 | 11 | 14 |
| 30 Jun 23 | 0 | -25 | 10 | 15 |
| 31 Mar 23 | 0 | -24 | 9 | 16 |
| 31 Dec 22 | 0 | -23 | 8 | 17 |
| 30 Sep 22 | 0 | -25 | 7 | 19 |
| 30 Jun 22 | 0 | -24 | 7 | 19 |
| 31 Mar 22 | 0 | -26 | 7 | 20 |
| 31 Dec 21 | 0 | -25 | 6 | 20 |
| 30 Sep 21 | 0 | -20 | 6 | 16 |
| 30 Jun 21 | 0 | -19 | 7 | 15 |
| 31 Mar 21 | 0 | -16 | 6 | 12 |
| 31 Dec 20 | 0 | -15 | 6 | 11 |
| 30 Sep 20 | 0 | -14 | 5 | 11 |
| 31 Dec 19 | 0 | -11 | 3 | 8 |
Quality Earnings: EVAX is currently unprofitable.
Growing Profit Margin: EVAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVAX is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare EVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: EVAX has a negative Return on Equity (-15487.84%), as it is currently unprofitable.